Allstate Corporation’s BioAtla BCAB Stock Holding History

Allstate Corporation’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-101	Closed	-$213K	–	696
2021 Q2	$213K	Buy	+101	New	+$228K	0.01%	701

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Allstate Corporation's BCAB Position: Q3 2021 in Review

Allstate Corporation sold out of BioAtla (BCAB) in Q3 2021, closing a stake of 101 shares — an estimated $213K sold.

Allstate Corporation first reported a position in BCAB in Q2 2021 and held it in 1 quarter. The position peaked at $213K in Q2 2021. 86 funds tracked by Wall St. Rank hold BCAB as of Q3 2021.

Allstate Corporation reported no remaining BioAtla position as of Q3 2021 after selling out during the quarter.
Allstate Corporation sold 101 BioAtla shares in Q3 2021, an estimated $213K.
Allstate Corporation first reported a position in BioAtla in Q2 2021 and held it in 1 quarter.
Allstate Corporation's BioAtla position peaked at $213K in Q2 2021.
86 funds tracked by Wall St. Rank held BioAtla as of Q3 2021.

Based on Allstate Corporation's 13F filing for Q3 2021, filed 15 Nov 2021.